JØ

Jeppe Øvlesen

SynAct Pharma AB

Insider activity · 24 months0 buys1 saleCumulative net flow

Dec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 1 saleOct 26 · 0 buys · 0 salesNov 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€239k

Latest filing published 07 Sept 2026 for SynAct Pharma AB, €239k.

Filing timeline

BuySale

Jeppe Øvlesen

Insider track record

Disclosed buys

Disclosed sells

Signal history

Jeppe Øvlesen: trading record in brief

Jeppe Øvlesen discloses dealings in SynAct Pharma AB to Finansinspektionen. Over a trading history stretching from 22 November 2019 to 2 September 2026, the count stands at 10 filings.

Every open-market trade on record is a sale: 1 sale worth €239k. So far in 2026, the count stands at no purchases and 1 sale.

The record was last updated on 7 September 2026 with an open-market sale (€239k) in SynAct Pharma AB. Typically, a trade is published a median of 4 days after it takes place. Under the Market Abuse Regulation, managers have three business days to notify their trades. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.

Companies and markets linked to Jeppe Øvlesen

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

SynAct Pharma AB (SE)

Declarations10 total

▼
Jeppe Øvlesen
Verkställande direktör (VD)Executives2 Sept 2026SynAct Pharma AB
3M SEK37FI-SE
150,000 shares@ SEK 17.800.28% mcap100.0% of flowAktieISIN SE0008241491FI:csv-04882b33788f2d98072d
●
Jeppe Øvlesen
Verkställande direktör (VD), StyrelseledamotExecutives30 Dec 2024SynAct Pharma AB
250,002 SEK22FI-SE
28,902 shares@ SEK 8.650.3% of flowAktieISIN SE0008241491FI:csv-504306c51e785182722d
●
Jeppe Øvlesen
StyrelseledamotExecutives30 Apr 2024SynAct Pharma AB
499,995 SEK7FI-SE
58,139 shares@ SEK 8.600.6% of flowAktieISIN SE0008241491FI:csv-41df6a4686e6de60e8ad
●
Jeppe Øvlesen
Verkställande direktör (VD)Executives21 Mar 2024SynAct Pharma AB
2M SEK22FI-SE
245,870 shares@ SEK 6.902.1% of flowAktieISIN SE0008241491FI:csv-0d5afed31033847698b4
●
Jeppe Øvlesen
Verkställande direktör (VD)Executives16 Jan 2023SynAct Pharma AB
73M SEK30FI-SE
1,161,777 shares@ SEK 62.6092.2% of flowAktieISIN SE0008241491FI:csv-00572fbcfe11aa065693
●
Jeppe Øvlesen
Verkställande direktör (VD)Executives16 Jan 2023SynAct Pharma AB
865,445 SEK22FI-SE
13,825 shares@ SEK 62.601.1% of flowAktieISIN SE0008241491FI:csv-d8cd9b143c8902f51c47
●
Jeppe Øvlesen
CEO / Verkställande direktörExecutives10 Jul 2020SynAct Pharma AB
199,928 SEK23FI-SE
29,840 shares@ SEK 6.706.9% of flowAktieISIN SE0008241491FI:csv-88db0a0afcc9870685cd
●
Jeppe Øvlesen
CEO / Verkställande direktörExecutives10 Jul 2020SynAct Pharma AB
0FI-SE
29,840 shares0TeckningsoptionISIN SE0013409620FI:csv-c644b3c133a786cf2525
●
Jeppe Øvlesen
CEO/Verkställande direktörExecutives27 Nov 2019SynAct Pharma AB
185,008 SEK0FI-SE
7,460 shares@ SEK 24.806.3% of flowBTU (betald tecknad unit)ISIN SE0013409653FI:csv-14126a5b7fcf71ac972d
●
Jeppe Øvlesen
CEO / Verkställande direktörExecutives22 Nov 2019SynAct Pharma AB
0FI-SE
1,239,923 shares0AktieISIN SE0013409646FI:csv-ef295cceb637515ba9a5

10 of 10 declarations

Jeppe Øvlesen

Insider track record

Jeppe Øvlesen: trading record in brief

Companies and markets linked to Jeppe Øvlesen

Related entities